HansBioMed
HansBioMed is a privately held South Korean medical aesthetics and tissue engineering company that develops and distributes biologics (ECM injectables, dermal matrices, bone repair products) and medical devices (cohesive silicone breast implants, PDO lifting threads, hair transplanters) to clinics and hospitals across 100+ countries.
- Company typePrivate
- Founded1999
- HeadquartersSongpadong, South Korea
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What HansBioMed does
HansBioMed (한스바이오메드) is a South Korea-based, privately held medical aesthetics and biotechnology company founded in 1999 that develops and commercializes tissue-engineered biologics and medical devices for cosmetic and reconstructive procedures. Its product portfolio spans two main categories: Biologics, including the CellREDM ECM-based injectable skin booster, the SureDerm line of acellular dermal matrices and grafts, BellaGen dermal fillers, BellaCell HD, and a bone-repair family (SureFuse, ExFuse, Genesis Sponge Block, Pedi-Stick, SureChip, OSSTOP); and Medical Devices, including BellaGel and BOUNS cohesive silicone breast implants, MINT Lift PDO absorbable lifting threads, Elatens and EZ-Tcon thread products, E-ImplanTube insertion funnels, ScarClinic silicone scar management devices, and Lion HT/HN FDA-registered hair transplanters with patented clip needles.
The company operates from a Seoul headquarters (Songpa-gu) and a 1,800-pyeong Daejeon tissue engineering research center, and exports to 100+ countries through a mix of direct B2B field sales to clinics and hospitals, an international distributor network, and strategic distribution partnerships — most notably the April 2026 agreement with Hugel Inc. for CellREDM in Korea under a co-promotion model. Its Vision 2030 targets global #1 positioning in artificial breast implants, lifting threads, and human tissue products, alongside 500 billion KRW in revenue. The company maintains four wholly owned subsidiaries (HansCare, Hans pharma, ATEMs, Mint Medical) and a dedicated KOL/physician training platform (Live Academy) as its primary demand-generation engine.
Revenue is not publicly disclosed; the company is privately held with 251-500 employees and supports physician adoption through medical conference participation, hands-on training programs, brand websites, and global KOL networks. HansBioMed also operates an ongoing 10-year BellaGel long-term monitoring and retrospective observational study in response to a 2020 Korean MFDS sales suspension that was subsequently resolved without identified harmful substances, with related contingent liabilities declining from KRW 9.5B (2020) to KRW 2.8B (2025).
HansBioMed firmographics
Firmographics- Name
- HansBioMed
- Legal name
- HansBioMed (한스바이오메드)
- Website
- https://hansbiomed.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- HansBioMed is a privately held South Korean medical aesthetics and tissue engineering company that develops and distributes biologics (ECM injectables, dermal matrices, bone repair products) and medical devices (cohesive silicone breast implants, PDO lifting threads, hair transplanters) to clinics and hospitals across 100+ countries.
- Ownership category
- akta.pro rank
HansBioMed industry classification
Industry- Product category
- Medical Aesthetic Devices and Tissue Engineering Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where HansBioMed is headquartered
LocationHeadquarters
- HQ city
- Songpadong
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
HansBioMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of aesthetic medical devices including silicone implants, lifting threads, and surgical instruments to medical clinics and hospitals
- Biologics/Tissue Product Sales: Sale of tissue implants and biologics including skin boosters, bone grafts, and dermal fillers to healthcare providers
- Distribution/Partner Revenue: Revenue through distribution agreements such as the Hugel partnership for CellREDM™ in Korean market
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
HansBioMed product offering
Product offeringCore offering
HansBioMed develops and manufactures medical aesthetic and tissue engineering products, including silicone breast implants (BellaGel, BOUNS), PDO absorbable lifting threads (MINT Lift, Elatens, EZ-Tcon), ECM-based skin regeneration injectables (CellREDM), acellular dermal matrices (BellaCell HD, SureDerm), dermal fillers (BellaGen), bone grafts and hemostatic products (SureFuse, ExFuse, Pedi-Stick, OSSTOP), silicone scar management devices (ScarClinic), and hair transplant instruments (Lion HT/HN). Its offering is sold to medical aesthetics clinics, plastic surgery hospitals, and international distributors in 100+ countries, supported by physician training programs (Live Academy).
Product overview
HansBioMed is a Korean medical aesthetics and tissue engineering company offering a diversified portfolio spanning Biologics and Medical Devices. The Biologics portfolio includes skin regeneration products (CellREDM™ ECM-based injectable, SureDerm® line for dermal reconstruction, BellaGen™ dermal fillers, BellaCell HD™ acellular dermal matrix) and bone repair products (SureFuse®, ExFuse™, Genesis Sponge Block, Pedi-Stick®, SureChip™, OSSTOP™). The Medical Devices portfolio includes aesthetic thread products (MINT Lift® PDO threads, Elatens, EZ-Tcon™), breast implants (BOUNS™ silicone implants), surgical accessories (E-ImplanTube™ implant funnel, ScarClinic™ silicone scar management), and hair transplantation devices (Lion HT/HN). The company also maintains the BellaGel brand for breast implants as a separate sub-brand.
Differentiator
Problem solved
Functional benefit
Brands
- BellaGel: Silicone breast implant brand including BellaGel and BOUNS products
- MINT Lift
- EZ-Tcon
- SureDerm
- klardie
- beautydaum
Products and services
- MINT Lift® PDO-based absorbable lifting threads for facial rejuvenation procedures.
- Elatens Thread lifting product for aesthetic procedures.
- EZ-Tcon™
- Lion HT/HN
- ScarClinic™
- BOUNS™
- E-ImplanTube™
- CellREDM™ ECM-based injectable skin booster treatment for skin regeneration, distributed in Korea through partnership with Hugel.
- SureDerm® Implant
- SureDerm® Graft
- SureDerm™ Repair
- BellaCell HD™
- BellaGen™
- BellaGen™ Plus
- BellaGen™ Tablet
- SureFuse®
- ExFuse™
- Genesis Sponge Block
- Pedi-Stick®
- Pedi-Stick® Plus
- SureChip™
- OSSTOP™
Quantifiable outcome
- Sustained revenue growth since establishment
Companies that use HansBioMed
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
HansBioMed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
HansBioMed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Hugel Inc.coreHugel signed a distribution agreement with Hans Biomed on April 1, 2026 (announced March 31) to sell CellREDM™, an ECM-based injectable treatment, in the Korean market. The partnership enables Hugel to expand beyond botulinum toxin and dermal fillers into skin regeneration. Both companies indicated this marks the beginning of broader expansion plans, with Hugel planning to explore additional innovative aesthetic materials including PLLA, PCL, PN, and PDRN. A co-promotion model is being developed tailored to specialized clinics.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
HansBioMed competitors and assessment
Company assessmentDirect peers
- Polytech Health & Aesthetics: German-based manufacturer of silicone breast implants and aesthetic medical devices serving plastic surgeons worldwide. Comparable product portfolio (textured/smooth implants, expanders) and B2B sales model to clinics matching HansBioMed's BellaGel/BOUNS business.
- Establishment Labs: Public medical technology company developing and manufacturing silicone breast implants and related surgical devices under the Motiva brand. Directly comparable to HansBioMed's BellaGel/BOUNS breast implant business and similar target customer base of plastic surgeons globally.
- GC Aesthetics: Global medical aesthetics company focused on silicone breast implants (Perthese, Eurosilicone, Round and anatomical implants) and post-mastectomy reconstruction. Direct competitor to HansBioMed's BOUNS/BellaGel in the breast implant category with overlapping surgeon customer base.
- Sinclair Pharma (Galderma-owned): Specialty aesthetics company with PDO lifting threads, hyaluronic acid fillers (MaiLi), and regenerative skin boosters — directly overlapping HansBioMed's MINT Lift thread and BellaGen filler offerings, serving the same plastic surgery clinics.
- Suneva Medical: Regenerative aesthetics company selling dermal fillers (Bellafill), regenerative tissue (Puregraft fat grafting), and skincare — comparable to HansBioMed's biologies and tissue regeneration portfolio (SureDerm, BellaGen, BellaCell HD) with similar physician-office channel.
- Hugel Inc. Korean medical aesthetics leader selling botulinum toxin (Botulax), dermal fillers (Chaeum), and now distributing HansBioMed's CellREDM. Competes in the same Korean aesthetics clinics and overlapping product categories (skin boosters, fillers), and is also HansBioMed's strategic distribution partner.
Broad incumbents
- Allergan Aesthetics (AbbVie): Divisions of AbbVie covering breast implants (Natrelle), dermal fillers (Juvederm), biostimulators (Sculptra), and botox. Broad incumbent across virtually every category HansBioMed competes in, with much deeper R&D and commercial scale; serves as the primary competitive benchmark in medical aesthetics.
- Galderma: Global dermatology/aesthetics leader with Restylane fillers, Sculptra biostimulator, and skincare lines. Comparable to HansBioMed's aesthetics/biologics business but as a much larger multi-product incumbent with broader dermatology portfolio.
Emerging players
- APT Medical (Aesthetics): Korean/Asian aesthetics developer specializing in PDO lifting threads, fillers, and skin boosters for plastic surgery clinics. Direct overlap with HansBioMed's MINT Lift thread business and competitive presence in similar Asia-Pacific aesthetics markets.
- Evotech (Eurothreads, Mesh): European aesthetics device maker focused on PDO and PCL thread lifting products similar to HansBioMed's MINT Lift. Comparable product format and physician customer base, but with smaller geographic footprint and limited brand recognition versus MINT Lift.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
HansBioMed social profiles
Digital presenceHansBioMed compliance and trust
Trust signalCompliance2 records
HansBioMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
HansBioMed leadership team
Management profileNumber of profiles
Profiles1 record
HansBioMed subsidiaries and ownership
Company hierarchySubsidiaries4 records
HansBioMed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HansBioMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HansBioMed
What does HansBioMed do?
HansBioMed develops and manufactures medical aesthetic and tissue engineering products, including silicone breast implants (BellaGel, BOUNS), PDO absorbable lifting threads (MINT Lift, Elatens, EZ-Tcon), ECM-based skin regeneration injectables (CellREDM), acellular dermal matrices (BellaCell HD, SureDerm), dermal fillers (BellaGen), bone grafts and hemostatic products (SureFuse, ExFuse, Pedi-Stick, OSSTOP), silicone scar management devices (ScarClinic), and hair transplant instruments (Lion HT/HN). Its offering is sold to medical aesthetics clinics, plastic surgery hospitals, and international distributors in 100+ countries, supported by physician training programs (Live Academy).
Is HansBioMed a public or private company?
HansBioMed is a private company. It is classified as unknown and is currently operating.
When was HansBioMed founded?
HansBioMed was founded in 1999. It employs 251 to 500 people.
Where is HansBioMed based?
HansBioMed is headquartered in Songpadong, South Korea, in the Asia region.
How does HansBioMed make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are biologics/Tissue Product Sales and distribution/Partner Revenue.
Who are HansBioMed's main competitors?
Direct peers on record are Polytech Health & Aesthetics, Establishment Labs, GC Aesthetics, Sinclair Pharma (Galderma-owned), Suneva Medical and Hugel Inc.. Broad incumbents are Allergan Aesthetics (AbbVie) and Galderma. Emerging players are APT Medical (Aesthetics) and Evotech (Eurothreads, Mesh).
Does HansBioMed have an API?
No public API is recorded for HansBioMed.
What industry is HansBioMed in?
HansBioMed's product category is Medical Aesthetic Devices and Tissue Engineering Products. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 3842.